Affordable Access

deepdyve-link
Publisher Website

Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine

Authors
  • Stein, Dan J.1
  • 1 University of Cape Town,
Type
Published Article
Journal
Advances in Therapy
Publisher
Springer Healthcare
Publication Date
Aug 21, 2021
Volume
38
Issue
Suppl 2
Pages
52–60
Identifiers
DOI: 10.1007/s12325-021-01860-1
PMID: 34417992
PMCID: PMC8437845
Source
PubMed Central
Keywords
Disciplines
  • Review
License
Unknown

Abstract

Recent network meta-analyses support the use of pharmacotherapy in patients with generalised anxiety disorder (GAD). Compared with placebo, drug treatment can improve symptoms and quality of life, and is more effective in preventing relapse. Selective serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors are generally considered the first-line agents of choice in GAD, but in some patients, an alternative evidence-based treatment with a different mechanism of action may also be considered (e.g. those with severe GAD, inadequate response, adverse effects and/or contraindications). One example is agomelatine, a melatonin receptor agonist and serotonin 2C (5-HT2C) receptor antagonist, which has been shown to have efficacy that is greater than placebo in patients with GAD, and to have a tolerability profile that compares favourably with that of escitalopram. Both agomelatine and escitalopram are efficacious in treating patients with GAD, including those with severe symptoms. Video Abstract Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01860-1.

Report this publication

Statistics

Seen <100 times